Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | A better understanding of smoldering myeloma to detect and prevent progression to multiple myeloma

Claudio Cerchione • 27 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, comments on the importance of better understanding smoldering myeloma in order to better stratify patients in risk categories and effectively detect and prevent progression to multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Claudio Cerchione

6:48
Key trials in multiple myeloma presented at ASH 2023: take home messages
Claudio Cerchione • 11 Dec 2023
4:58
Novel immunotherapies transforming R/R myeloma treatment: bispecifics, CAR-T cells & more
Claudio Cerchione • 28 Sep 2023
3:15
Promising triplets and agents in R/R myeloma: SVd, Isa-Kd and melflufen
Claudio Cerchione • 28 Sep 2023
2:34
The role of FDG-PET plus whole body MRI in staging patients with high-risk SMM & R/R myeloma
Claudio Cerchione • 28 Sep 2023

Related Videos

2:24
Primary prevention against atherosclerosis in patients with hemophilia
Beverley Hunt • 29 Apr 2024
3:05
The development of iNKT-CAR T-cells for hematological malignancies
Kanagaraju Ponnusamy • 29 Apr 2024
1:40
The current therapeutic landscape for indolent and advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
1:33
Post-hoc analysis of TOURMALINE-MM1 data while adjusting for subsequent therapies
Karthik Ramasamy • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals